Using publicly available genomic datasets, the prevalence of ESR1 and ESR2 gene mutations or copy number variations in patients with metastatic or advanced PCa was 4% (5/150) compared to 2% (11/492) in patients with early PCa [102]. This evidence concerns the gene ESR1 and posterior cortical atrophy.